Dimerix Ltd
Research Dimerix Ltd (DXB) on Bullrun: market cap AUD 126.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDXB
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 126.08M
- Financial periodFY2025
- RevenueAUD 5.59M
- Revenue growth1271.1%
- Net income-AUD 13.25M
- Free cash flowAUD 39.03M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 126.08M.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Frequently asked questions
What is Dimerix Ltd's market cap?
Dimerix Ltd's market capitalization is AUD 126.08M.
What does Dimerix Ltd do?
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19;